[1]GAYEN S.Malignant pleural effusion:Presentation,diagnosis,and management[J].Am J Med,2022,135(10):1188-1192.
[2]SPILIOTIS J,HALKIA E,DE BREE E.Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives[J].Current Oncology(Toronto,Ont),2016,23(3):e266-e275.
[3]ACS M,BABUCKE M,JUSUFI M,et al.Current clinical practices of cytoreductive surgery(CRS) and hyperthermic intraperitoneal chemotherapy(HIPEC)[J].Innov Surg Sci,2024,9(1):3-15.
[4]REESE M,EICHELMANN AK,NOWACKI TM,et al.The role of cytoreductive surgery and HIPEC for the treatment of primary and secondary peritoneal malignancies-experience from a tertiary care center in Germany[J].Langenbecks Arch Surg,2024,409(1):113.
[5]AWAD A,AWAD M,ALAMI M,et al.Successful treatment of pseudomyxoma peritonei(PMP) through cytoreductive surgery and hyperthermic intraperitoneal chemotherapy(CRS-HIPEC):A case report and literature review[J].Int J Surg Case Rep,2024,119:109656.
[6]FALLA-ZUNIGA LF,SARDI A,KING MC,et al.Peritoneal metastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy(CRS/HIPEC)[J].Pleura Peritoneum,2024,9(1):15-22.
[7]LANGELLOTTI L,FIORILLO C,D'ANNIBALE G,et al.Efficacy of cytoreductive surgery(CRS)+HIPEC in gastric cancer with peritoneal metastasis:Systematic review and meta-analysis[J].Cancers(Basel),2024,16(10):1929.
[8]LAVOUE V,OULDAMER L,HUCHON C.Correspondence on "Complications of HIPEC for ovarian cancer surgery:evaluation over two time periods" by Navarro Santana et al [J].Int J Gynecol Cancer,2024,34(6):965.
[9]MOLDOVAN B,SAON CT,ADAM II,et al.Successful implementation of HITOC and HIPEC in the management of advanced ovarian carcinoma with pleural and peritoneal carcinomatosis[J].Diagnostics(Basel),2024,14(5):455.
[10]SAQIB HWU,ABDULLAH A,MAJID A."Unveiling controversies:The role of HIPEC in colorectal cancer peritoneal metastasis"[J].Eur J Surg Oncol,2024,50(6):108345.
[11]RIED M,EICHHORN M,WINTER H,et al.Expert recommendation for the implementation of hyperthermic intrathoracic chemotherapy(HITOC) in Germany[J].Zentralblatt Fur Chirurgie,2020,145(1):89-98.
[12]LI Y,ZHOU YF,LIANG H,et al.Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies[J].World Journal of Gastroenterology,2016,22(30):6906-6916.
[13]TURAGA K,LEVINE E,BARONE R,et al.Consensus guidelines from the American society of peritoneal surface malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy(HIPEC) in colorectal cancer patients in the United States[J].Annals of Surgical Oncology,2014,21(5):1501-1505.
[14]ATES O,AKSEL B,AKKUS MH,et al.HIPEC in ovarian cancer:When and to whom[J].Journal of the College of Physicians and Surgeons-Pakistan:JCPSP,2023,33(9):1001-1005.
[15]SUN BJ,DANIEL SK,LEE B.The role of prophylactic and adjuvant hyperthermic intraperitoneal chemotherapy(HIPEC) in prevention of peritoneal metastases in advanced colorectal cancer[J].Journal of Clinical Medicine,2023,12(20):6443.
[16]WONG EYT,TAN GHC,CHIA CSL,et al.Morbidity and mortality of elderly patients following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy(HIPEC)[J].Asia-Pacific Journal of Clinical Oncology,2018,14(2):e193-e202.
[17]TSUYOSHI H,INOUE D,KUROKAWA T,et al.Hyperthermic intraperitoneal chemotherapy(HIPEC) for gynecological cancer[J].The Journal of Obstetrics and Gynaecology Research,2020,46(9):1661-1671.
[18]CHEN Z,ALI M,KAI Z,et al.HIPEC with CRS versus cytoreductive surgery(CRS) for the gastric cancer metastasis to peritoneum[J].Clinical & Translational Oncology:Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico,2023,25(4):1011-1016.
[19]LU C,LI L,LUO Z,et al.Clinical efficacy of type-B ultrasound-guided intraperitoneal hyperthermic chemoperfusion combined with systemic chemotherapy in advanced gastric cancer patients with malignant ascites[J].Neoplasma,2016,63(2):299-303.
[20]CEELEN WP,VAN NIEUWENHOVE Y,VAN BELLE S,et al.Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer[J].Annals of Surgical Oncology,2012,19(7):2352-2359.
[21]REICHMAN TW,CRACCHIOLO B,SAMA J,et al.Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma[J].Journal of Surgical Oncology,2005,90(2):51-58.
[22]KNIGSRAINER I,HORVATH P,STRULLER F,et al.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases:a single centre experience[J].Langenbeck's Archives of Surgery,2014,399(5):589-594.
[23]PITEK S,SARNOWSKA E,KACPERCZYK-BARTNIK J,et al.Discrepancy between recommendations regarding hyperthermic intraperitoneal chemotherapy(HIPEC) in ovarian cancer management:a narrative review[J].Chin Clin Oncol,2024,13(3):37.
[24]DELLA CORTE L,CONTE C,PALUMBO M,et al.Hyperthermic intraperitoneal chemotherapy(HIPEC):New approaches and controversies on the treatment of advanced epithelial ovarian cancer-systematic review and meta-analysis[J].Journal of Clinical Medicine,2023,12(22):7012.
[25]DELLINGER TH.HIPEC in the consolidation setting:A consolation prize for chemorefractory ovarian cancer[J].Annals of Surgical Oncology,2023,30(6):3177-3179.
[26]MARGIOULA-SIARKOU C,ALMPERIS A,PAPANIKOLAOU A,et al.HIPEC for gynaecological malignancies:A last update(Review)[J].Medicine International,2023,3(3):25.
[27]COTTE E,COLOMBAN O,GUITTON J,et al.Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure[J].Journal of Clinical Pharmacology,2011,51(1):9-18.
[28]ANSALONI L,COCCOLINI F,MOROSI L,et al.Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer[J].British Journal of Cancer,2015,112(2):306-312.
[29]ZIVANOVIC O,ABRAMIAN A,KULLMANN M,et al.HIPEC ROC I:a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer[J].International Journal of Cancer,2015,136(3):699-708.
[30]AMBROGI MC,KORASIDIS S,LUCCHI M,et al.Pleural recurrence of thymoma:surgical resection followed by hyperthermic intrathoracic perfusion chemotherapy[J].European Journal of Cardio-thoracic Surgery,2016,49(1):321-326.
[31]VAN DRIEL WJ,KOOLE SN,SIKORSKA K,et al.Hyperthermic intraperitoneal chemotherapy in ovarian cancer[J].N Engl J Med,2018,378(3):230-240.
[32]LIU L,ZHANG N,MIN J,et al.Retrospective analysis on the safety of 5 759 times of bedside hyperthermic intra-peritoneal or intra-pleural chemotherapy(HIPEC)[J].Oncotarget,2016,7(16):21570-21578.
[33]LIU L,SUN L,ZHANG N,et al.A novel method of bedside hyperthermic intraperitoneal chemotherapy as adjuvant therapy for stage-Ⅲ gastric cancer[J].International Journal of Hyperthermia,2022,39(1):239-245.
[34]LIU L,ZHANG T,SONG X,et al.Hyperthermic intrathoracic/intraperitoneal chemotherapy versus conventional intrapleural/intraperitoneal chemotherapy for the malignant effusion:a multi-center randomized clinical trial[J].International Journal of Hyperthermia,North American Hyperthermia Group,2023,40(1):2241689.